Table 6.
Progress in the treatment of CLL
| Study/treatment | No. | CR % | OR % | PFS, mo | Reference |
|---|---|---|---|---|---|
| CALGB 9011 | |||||
| Chlorambucil | 181 | 4 | 37 | 14 | Rai et al (2000)54 |
| Fludarabine | 170 | 20 | 63 | 20 | |
| GCLLSG CLL5 (elderly patients only) | |||||
| Chlorambucil | 100 | 0 | 51 | 18 | Eichhorst et al (2009)55 |
| Fludarabine | 93 | 7 | 72 | 19 | |
| CAM 307 | |||||
| Chlorambucil | 148 | 2 | 55 | 11.7 | Hillmen et al (2007)56 |
| Alemtuzumab | 149 | 24 | 83 | 14.6 | |
| GCLLSG CLL4 | |||||
| Fludarabine | 180 | 7 | 83 | 20 | Eichhorst et al (2006)57 |
| Fludarabine/cyclophosphamide | 182 | 24 | 94 | 48 | |
| ECOG E2997 | |||||
| Fludarabine | 137 | 5 | 59 | 19 | Flinn et al (2007)58 |
| Fludarabine/cyclophosphamide | 141 | 23 | 74 | 32 | |
| LRF CLL4 | |||||
| Chlorambucil | 366 | 7 | 72 | 20 | Catovsky et al (2007)59 |
| Fludarabine | 181 | 15 | 80 | 23 | |
| Fludarabine/cyclophosphamide | 182 | 38 | 92 | 43 | |
| MDACC (phase 2) | |||||
| Rituximab/fludarabine/cyclophosphamide | 300 | 72 | 95 | 80 | Tam et al (2008)60 |
| GCLLSG CLL8 | |||||
| Fludarabine/cyclophosphamide (FC) | 408 | 23 | 85 | 32.3 | Hallek et al (2008)61 |
| Rituximab/fludarabine/cyclophosphamide (R-FC) | 409 | 45 | 95 | 39.8 |
CR indicates complete response; OR, overall response; PFS, progression-free survival; CALGB, Cancer and Leukemia Group B; GCLLSG, German CLL study group; ECOG, Eastern Cooperative Oncology Group; LRF, Leukaemia Research Fund; and MDACC, M. D. Anderson Cancer Center.